19 DIC. 2022 · In the third and final episode, Desmond Cabrera, global lead for cell and gene therapy at Allucent, shares how small- and mid-sized companies can operationalize cell and gene therapy trials.

14 DIC. 2022 · In the second episode, Pavle Vukojevic, a rheumatologist turned clinical researcher who is now the chief scientific officer at Allucent, explains why multinational clinical trials are key to bringing novel therapies to market.

12 DIC. 2022 · In the first episode, MerriBeth Adams, PhD, senior vice president of the consulting business unit at Allucent, discusses how developing a regulatory strategy can save you time and money while setting you up for success in bringing treatments to patients. We also dive into the critical importance of a gap analysis and the characteristics of an effective regulatory strategy.